Manuel Menéndez-González, Tamba Bogdan-Ionel, Leclere Maxime, Mabrouk Mostafa, Schreiner Thomas-Gabriel, Ciobanu Romeo, Cristina Tomás-Zapico
Facultad de Medicina y Ciencias de la Salud, Universidad de Oviedo, Calle Julián Clavería s/n, 33006 Oviedo, Spain.
Department of Neurology, Hospital Universitario Central de Asturias, Avenida Roma s/n, 33011 Oviedo, Spain.
Pharmaceutics. 2023 Feb 25;15(3):768. doi: 10.3390/pharmaceutics15030768.
Intrathecal pseudodelivery of drugs is a novel route to administer medications to treat neurodegenerative diseases based on the CSF-sink therapeutic strategy by means of implantable devices. While the development of this therapy is still in the preclinical stage, it offers promising advantages over traditional routes of drug delivery. In this paper, we describe the rationale of this system and provide a technical report on the mechanism of action, that relies on the use of nanoporous membranes enabling selective molecular permeability. On one side, the membranes do not permit the crossing of certain drugs; whereas, on the other side, they permit the crossing of target molecules present in the CSF. Target molecules, by binding drugs inside the system, are retained or cleaved and subsequently eliminated from the central nervous system. Finally, we provide a list of potential indications, the respective molecular targets, and the proposed therapeutic agents.
鞘内药物假递送是一种基于脑脊液汇流治疗策略，通过可植入装置给药治疗神经退行性疾病的新途径。虽然这种疗法的开发仍处于临床前阶段，但与传统给药途径相比，它具有显著优势。在本文中，我们描述了该系统的原理，并提供了一份关于作用机制的技术报告，该机制依赖于使用具有选择性分子渗透性的纳米多孔膜。一方面，这些膜不允许某些药物通过；而另一方面，它们允许脑脊液中存在的靶分子通过。靶分子通过在系统内结合药物，被保留或裂解，随后从中枢神经系统中清除。最后，我们列出了潜在的适应症、各自的分子靶点以及拟用的治疗药物。
